Have you been diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent (dupilumab)?  Have you wondered what caused your CTCL?   If so, you may be entitled to compensation.   Contact Mazie Slater to have your potential case evaluated.

Mazie Slater is based in New Jersey, where litigation is likely to be located because Sanofi-Aventis, a New Jersey based pharmaceutical company, partnered in the development and marketing of the drug.  The other developer, Regeneron, is located nearby in Tarrytown, New York.

Mazie Slater has extensive experience litigating against pharmaceutical companies, and has been appointed to leadership positions and has actually gone to trial for plaintiffs in large pharmaceutical and medical device litigations.

The primary indication for Dupixent is treatment of Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition. It causes red, itchy, scaly patches, flares, and sometimes skin thickening or “lichenification.”  AD often appears in childhood but can persist or begin in adulthood. Many patients experience cycles of improvement and worsening.  Severe or refractory AD can be difficult to control with topical therapies and may involve systemic inflammation and immune dysregulation.

Dupixent is part of a class of biologic / monoclonal antibody therapies designed to target specific immune pathways driving inflammation, rather than broadly suppressing the immune system.  Dupixent is approved for treatment of moderate-to-severe atopic dermatitis (especially when topical treatments are inadequate) as well as other conditions with allergic inflammation (e.g. asthma, chronic rhinosinusitis). 

Dupixent is also prescribed off label (meaning for conditions not listed as approved by the FDA) by physicians, including for example:

As part of the immune system, skin plays a major role in the lymphatic system. Certain cancers of the lymph system are known as Lymphomas.  Cutaneous T-Cell Lymphoma or CTCL is a type of cancer that originates in the skin. It is one of the non-Hodgkins Lymphoma group of cancers that affects a certain type of white blood cell known as T-cells.  In cutaneous T-cell lymphoma, T lymphocytes mutate into cancerous cells that multiply uncontrollably. CTCL may include subtypes of Cutaneous T-cell Lymphoma including Sezary Syndrome, Mycosis Fungoides, and other T-cell Lymphoma subtypes.

Symptoms of cutaneous T-cell lymphoma include:

Dupixent was initially viewed as a safer long-term option for many patients with severe AD. But over the last few years, reports in the scientific literature have raised concerns that Dupixent may contribute to the development of CTCL. 

Beginning around 2020, researchers and physicians started publishing case reports and clinical studies raising concern about a possible connection between Dupixent (dupilumab) and the development of Cutaneous T-Cell Lymphoma (CTCL). The emerging data suggests that patients treated with Dupixent may face a substantially higher likelihood of developing this rare form of skin cancer compared to those who have not taken the drug.  There is also data indicating that Dupixent can cause progression of CTCL as well.

Recent medical analyses indicate that Dupixent use is associated with as much as a 4.5 fold (350%) increase in CTCL risk.

Our investigation shows that the drug manufacturers were aware, or should have been aware, of these potential dangers yet failed to adequately warn patients, physicians, and the broader medical community about the risks.  This is a violation of product liability law.

Our attorneys can help determine if you have grounds to file a CTCL lawsuit against the manufacturers and sellers of Dupixent and explain what will be needed to win your case. If you were diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent (dupilumab), contact us to investigate your situation, and discuss your options for a lawsuit.